Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on April 23, 2025
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025
GlobeNewswire
·
April 23, 2025
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025 Présentations sur l’actif propriétaire Tedopi® et sur deux inhibiteurs de SIRPα développés en partenariat avec Boehringer Ingelheim NANTES, France, 23 avril …
Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting
GlobeNewswire
·
April 23, 2025
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced topline results, reinforcing the potential of Nck modulation …
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC …
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
GlobeNewswire
·
April 23, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib …
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
GlobeNewswire
·
April 23, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Update: Dental Implants and Prosthetics market to grow at a CAGR of 5.4% during the forecast period (2025 – 2030): Wissen Research
GlobeNewswire
·
April 23, 2025
Sheridan, April 23, 2025 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global dental implants and prosthetics market is valued at 12.1 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 5 …
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
GlobeNewswire
·
April 23, 2025
— Oral presentation Tuesday, June 3, 2025 in Chicago — LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL …
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from …
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
GlobeNewswire
·
April 23, 2025
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass …
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
GlobeNewswire
·
April 23, 2025
HOUSTON, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion and launch of …
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
GlobeNewswire
·
April 23, 2025
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and …
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
GlobeNewswire
·
April 23, 2025
Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (" …
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
GlobeNewswire
·
April 23, 2025
SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its participation in the 15th Annual …
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
GlobeNewswire
·
April 23, 2025
Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return …
Bluejay Therapeutics Announces Upcoming Presentation of Preclinical Data in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at European Association for the Study of the Liver (EASL) Congress 2025
GlobeNewswire
·
April 23, 2025
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced it will present …
Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
GlobeNewswire
·
April 23, 2025
Kennewick, WA, April 23, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide …
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Detection of H. pylori Infection
GlobeNewswire
·
April 23, 2025
10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer Approximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogen This test …
OneMedNet and Protege Partner to Advance the Future of AI-Driven Healthcare with Real-Time, Multimodal Data
GlobeNewswire
·
April 23, 2025
MINNEAPOLIS, April 23, 2025 (GLOBE NEWSWIRE) -- OneMedNet, a leader in AI-powered Real-World Data, has announced a strategic partnership with Protege, the AI training data platform, to enable real-time access, multimodal patient data for AI developers and …
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
GlobeNewswire
·
April 23, 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing …